ALTO-100
Phase 2Small molecule
ALTO-100 is one of 56 small molecule programs targeting Bipolar Disorder. It is currently in Phase 2.
1
Indications
4
Total Trials
1
Active Trials
55
Competitors
Pipeline
Status by Indication[3][1]
Indication
Competition
Competitive Landscape
89 competitors in Bipolar Disorder
#DrugCompanyPhaseTrials
1Risperdal
WWim Janssens
Approved
Tegretol
NovartisApproved
Zofran
NovartisApproved
Ozempic
Novo NordiskApproved
Vyvanse
TakedaApproved
Vraylar
AbbVieApproved
Keppra
UCBApproved
Brintellix
TakedaApproved
Ritalin
NovartisApproved
Nolvadex
AstraZenecaApproved
Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.
Timeline
Expected Milestones
Clinical
Trials by Indication[1]
Sources
References
- [1]
- [2]
- [3]Open Targets Platform — Drug–disease associations for ALTO-100. EMBL-EBI & Wellcome Sanger Institute.
- [4]
Details
Drug Info
Quick Facts
- Modality
- Small molecule[2]
- Highest Phase
- Phase 2[1]
- Company
- AAlto Neuroscience